Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry

C A Griffith, L J Owen, R Body, Garry McDowell, B G Keevil

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Current gold standard markers for myocardial damage are troponins I and T, which are both sensitive and specific for the detection of myocardial infarction, but require up to 6 h to become reliably elevated in serum. Investigation into markers with potential to identify patients with early ischaemic changes is therefore intense. Choline is reported to be prognostic in patients presenting with acute coronary syndromes via its release from ischaemic cell membranes. Methods Liquid chromatography tandem mass spectrometry was used to develop a method to quantitate choline in plasma and blood. The method involves addition of a deuterated internal standard to an aliquot of plasma or blood followed by organic solvent addition, which precipitates the proteins in the sample. Preparation was carried out directly into a 96-deep-well plate. Chromatography of choline used a strong cation exchange column and separation used a Waters Atlantis dC18 analytical column positioned directly before the mass spectrometer source, allowing on-line preanalytical clean up of the sample. Results The lower limit of quantitation was 0.38 μmol/L, linearity was observed up to 754 μmol/L, with a working concentration range of 0.38–224 μmol/L, inter- and intra-assay coefficients of variation were <6% and <4%, respectively. Samples were stable throughout five freeze–thaw cycles and recovery was between 94% and 114%. Conclusions The assay was successfully validated in accordance with FDA guidelines and is suitable for quantitation of choline in research and clinical settings.
Original languageEnglish
Pages (from-to)56-61
JournalAnnals of Clinical Biochemistry
Volume47
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Liquid chromatography
Tandem Mass Spectrometry
Choline
Liquid Chromatography
Mass spectrometry
Blood
Plasmas
Assays
Chromatography
Troponin T
Troponin I
Mass spectrometers
Cell membranes
Acute Coronary Syndrome
Organic solvents
Cations
Precipitates
Ion exchange
Myocardial Infarction
Cell Membrane

Cite this

Griffith, C A ; Owen, L J ; Body, R ; McDowell, Garry ; Keevil, B G. / Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry. In: Annals of Clinical Biochemistry. 2010 ; Vol. 47, No. 1. pp. 56-61.
@article{7abdaf0ec8a74734be872151a53bb319,
title = "Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry",
abstract = "Background Current gold standard markers for myocardial damage are troponins I and T, which are both sensitive and specific for the detection of myocardial infarction, but require up to 6 h to become reliably elevated in serum. Investigation into markers with potential to identify patients with early ischaemic changes is therefore intense. Choline is reported to be prognostic in patients presenting with acute coronary syndromes via its release from ischaemic cell membranes. Methods Liquid chromatography tandem mass spectrometry was used to develop a method to quantitate choline in plasma and blood. The method involves addition of a deuterated internal standard to an aliquot of plasma or blood followed by organic solvent addition, which precipitates the proteins in the sample. Preparation was carried out directly into a 96-deep-well plate. Chromatography of choline used a strong cation exchange column and separation used a Waters Atlantis dC18 analytical column positioned directly before the mass spectrometer source, allowing on-line preanalytical clean up of the sample. Results The lower limit of quantitation was 0.38 μmol/L, linearity was observed up to 754 μmol/L, with a working concentration range of 0.38–224 μmol/L, inter- and intra-assay coefficients of variation were <6{\%} and <4{\%}, respectively. Samples were stable throughout five freeze–thaw cycles and recovery was between 94{\%} and 114{\%}. Conclusions The assay was successfully validated in accordance with FDA guidelines and is suitable for quantitation of choline in research and clinical settings.",
author = "Griffith, {C A} and Owen, {L J} and R Body and Garry McDowell and Keevil, {B G}",
year = "2010",
doi = "10.1258/acb.2009.008191",
language = "English",
volume = "47",
pages = "56--61",
journal = "Annals of Clinical Biochemistry",
issn = "0004-5632",
publisher = "Royal Society of Medicine",
number = "1",

}

Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry. / Griffith, C A; Owen, L J; Body, R; McDowell, Garry; Keevil, B G.

In: Annals of Clinical Biochemistry, Vol. 47, No. 1, 2010, p. 56-61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry

AU - Griffith, C A

AU - Owen, L J

AU - Body, R

AU - McDowell, Garry

AU - Keevil, B G

PY - 2010

Y1 - 2010

N2 - Background Current gold standard markers for myocardial damage are troponins I and T, which are both sensitive and specific for the detection of myocardial infarction, but require up to 6 h to become reliably elevated in serum. Investigation into markers with potential to identify patients with early ischaemic changes is therefore intense. Choline is reported to be prognostic in patients presenting with acute coronary syndromes via its release from ischaemic cell membranes. Methods Liquid chromatography tandem mass spectrometry was used to develop a method to quantitate choline in plasma and blood. The method involves addition of a deuterated internal standard to an aliquot of plasma or blood followed by organic solvent addition, which precipitates the proteins in the sample. Preparation was carried out directly into a 96-deep-well plate. Chromatography of choline used a strong cation exchange column and separation used a Waters Atlantis dC18 analytical column positioned directly before the mass spectrometer source, allowing on-line preanalytical clean up of the sample. Results The lower limit of quantitation was 0.38 μmol/L, linearity was observed up to 754 μmol/L, with a working concentration range of 0.38–224 μmol/L, inter- and intra-assay coefficients of variation were <6% and <4%, respectively. Samples were stable throughout five freeze–thaw cycles and recovery was between 94% and 114%. Conclusions The assay was successfully validated in accordance with FDA guidelines and is suitable for quantitation of choline in research and clinical settings.

AB - Background Current gold standard markers for myocardial damage are troponins I and T, which are both sensitive and specific for the detection of myocardial infarction, but require up to 6 h to become reliably elevated in serum. Investigation into markers with potential to identify patients with early ischaemic changes is therefore intense. Choline is reported to be prognostic in patients presenting with acute coronary syndromes via its release from ischaemic cell membranes. Methods Liquid chromatography tandem mass spectrometry was used to develop a method to quantitate choline in plasma and blood. The method involves addition of a deuterated internal standard to an aliquot of plasma or blood followed by organic solvent addition, which precipitates the proteins in the sample. Preparation was carried out directly into a 96-deep-well plate. Chromatography of choline used a strong cation exchange column and separation used a Waters Atlantis dC18 analytical column positioned directly before the mass spectrometer source, allowing on-line preanalytical clean up of the sample. Results The lower limit of quantitation was 0.38 μmol/L, linearity was observed up to 754 μmol/L, with a working concentration range of 0.38–224 μmol/L, inter- and intra-assay coefficients of variation were <6% and <4%, respectively. Samples were stable throughout five freeze–thaw cycles and recovery was between 94% and 114%. Conclusions The assay was successfully validated in accordance with FDA guidelines and is suitable for quantitation of choline in research and clinical settings.

U2 - 10.1258/acb.2009.008191

DO - 10.1258/acb.2009.008191

M3 - Article

VL - 47

SP - 56

EP - 61

JO - Annals of Clinical Biochemistry

JF - Annals of Clinical Biochemistry

SN - 0004-5632

IS - 1

ER -